logo
Plus   Neg
Share
Email

ITC Rules In Favor Of Apple In HTC Patent Litigation

The U.S. International Trade Commission, in a notice, said it has terminated an investigation against Apple Inc. (AAPL), stating that the Smartphone maker did not infringe patented technology held by Taiwan-based mobile handset maker HTC Corp.(HTCXF.PK).

The commission instituted this investigation on June 17, 2010, based on a complaint filed by HTC.

The complaint alleged violations of the Tariff Act of 1930 in the importation into the United States, the sale for importation, and sale within the United States after importation of certain portable electronic devices and related software by reason of infringement of various claims of certain patents.

On October 17, 2011, an administrative law judge issued a final initial determination, finding no violation of section 337 by Apple.

"Having examined the record of this investigation, including the administrative law judge's final initial determination, the Commission has determined that there is no violation of section 337," ITC said in its ruling.

by RTTNews Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Editors Pick
Billionaire entrepreneur Elon Musk on Thursday showed off his concept for the Loop, a high-speed underground public transportation system that will carry up to 16 people and travel at 150 miles per hour. At the Boring Company Information Session, Musk and project leader Steve Davis provided details of the underground mass transit tunnels that the Boring Co. plans to build beneath Los Angeles. Raden has become the second smart luggage company to shut down this month after major U.S. airlines banned smart luggage with non-removable batteries earlier this year. In a statement on its website, Raden said that it is no longer in operation and that all existing shipments have been processed for delivery. The company is shuttering after three years of operation. Shares of AstraZeneca were losing around 2 percent in the London trading after the British drug major reported Friday lower profit in its first quarter amid weak margin, despite growth in product sales. Further, the company reiterated its outlook for fiscal 2018. The level of Externalisation Revenue, divestment timing and investment in launches impacted the overall results.
Follow RTT